Figure. 3

MiR-31-5p inhibitor intrathecal injection induced pain hypersensitivities in naive mice. a The description of the animal experimental process. Behavior tests were performed after Scr(scramble) or inhibitor (miR-31-5p inhibitor) administration. b Relative expression of miR-31-5p in the DRG of navie mice treated with intrathecal miR-31-5p inhibitors/scrambles was determined by qRT-PCR. ^**P < 0.01 vs. naive. one-way ANOVA, n = 7 mice. c Effects of downregulated miR-31-5p on mechanical allodynia were assessed by withdrawal threshold on post-induction days 1, 2, and 3. ^* P < 0.05, ^** P < 0.01 vs. naive; Two-way ANOVA, n = 8 mice. d Effects of the downregulated miR-31-5p on thermal hyperalgesia were assessed by heat withdrawal latency at post-induction days 1, 2, and 3. ^*P < 0.05, ^**P < 0.01 vs. naïve. Two-way ANOVA, n = 8 mice. e–f Western blot analysis of P-ERK, ERK and GFAP protein expression in the spinal cord of naive mice at 3 days injected with intrathecal miR-31-5p inhibitor. ^**P < 0.01 vs. naive; two-way ANOVA, n = 3. RT-qPCR analysis of TNF‐α (g), IL‐6 (h) and IL‐1β (i) expression in the DRG of mice injected with Scr or inhibitor after 3 days. ^**P < 0.01, two- tailed unpaired t-test, n = 6 mice.